Senti Biosciences, Inc. (SNTI)
NASDAQ: SNTI · Real-Time Price · USD
3.244
-0.116 (-3.45%)
At close: Apr 1, 2025, 4:00 PM
3.302
+0.058 (1.79%)
After-hours: Apr 1, 2025, 4:07 PM EDT

Company Description

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases.

Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.

The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma.

It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells.

In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells.

The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors.

Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Senti Biosciences, Inc.
Senti Biosciences logo
Country United States
Founded 2016
Industry Biotechnology
Sector Healthcare
Employees 34
CEO Timothy Lu

Contact Details

Address:
2 Corporate Drive, First Floor
South San Francisco, California 94080
United States
Phone 650 239 2030
Website sentibio.com

Stock Details

Ticker Symbol SNTI
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001854270
CUSIP Number 81726A100
ISIN Number US81726A1007
Employer ID 86-2437900
SIC Code 2836

Key Executives

Name Position
Dr. Timothy K. Lu M.D., Ph.D. Co-Founder, Chief Executive Officer and Director
Dr. Kanya Rajangam M.D., Ph.D. President, Head of Research and Development and Chief Medical Officer
Dr. James J. Collins Ph.D. Scientific Co-Founder, Chairperson of Scientific Advisory Board and Independent Director
Yvonne Li M.B.A. Consultant
Dr. Wilson Wong Ph.D. Scientific Co-Founder and Member of Scientific Advisory Board
Jay Cross Chief Financial Officer
Faraz Siddiqui Senior Vice President of Technical Operations
Robert H. Cutler J.D. Senior Vice President and Head of Legal Affairs
Thomas P. Chung Vice President of Strategic Finance and Corporate Development
Dee Olomajeye Dragon Vice President of People and Culture Strategy & Head of Administrative Operations

Latest SEC Filings

Date Type Title
Mar 31, 2025 EFFECT Notice of Effectiveness
Mar 31, 2025 EFFECT Notice of Effectiveness
Mar 31, 2025 424B5 Filing
Mar 24, 2025 8-K Current Report
Mar 21, 2025 S-3 Registration statement under Securities Act of 1933
Mar 21, 2025 S-3 Registration statement under Securities Act of 1933
Mar 20, 2025 10-K Annual Report
Mar 20, 2025 8-K Current Report
Mar 17, 2025 SCHEDULE 13D Filing
Mar 17, 2025 SCHEDULE 13D/A Filing